Quarterly results for Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Limited – Q1 FY26 Results Summary
Announcement Date: August 1, 2025

Financial Highlights (Q1 FY26 vs Q1 FY25):
Revenue from operations: INR 3,587.28 Lakhs, down 7.5% YoY (Q1 FY25: INR 3,882.74 Lakhs) and down QoQ (Q4 FY25: INR 3,773.62 Lakhs)
EBITDA (proxy): INR 1,419.55 Lakhs; EBITDA margin approximately 39.3%
Net profit: INR 906.16 Lakhs, down 31.5% YoY (Q1 FY25: INR 1,323.62 Lakhs)
Net profit margin: 25.1%
Earnings per share (basic & diluted): INR 0.83, down from INR 1.21 YoY, reflecting increased paid-up equity (INR 1,089.65 Lakhs vs INR 726.44 Lakhs)
Balance Sheet / Capital:
Paid-up equity share capital increased significantly, indicating equity issuance or bonus shares.
Management Commentary & Strategic Updates:
The Board withdrew the previously approved merger with Themis Medicare Limited (TML) in June 2025 to focus on core fermentation-based pharmaceutical intermediates and APIs.
Commissioned a new multi-purpose API plant in Vapi, Gujarat, in May 2025 to enhance forward integration and strengthen exports to the US and Europe.
Dividend record date set for September 5, 2025.
Segment Performance:
Operates in a single segment: manufacturing of Bulk Drugs (pharmaceutical intermediates and APIs). No segmental or geographic breakdown provided.
Corporate Governance:
Appointment of Mr. Nihar Parikh as Additional Non-Executive Independent Director effective August 1, 2025.
Mr. Siddharth Kusumgar to step down as Independent Director on September 20, 2025.
Auditor’s Report:
Limited review by GMJ & Co. with no qualifications or concerns noted.
Outlook:
No explicit financial guidance provided; focus indicated on leveraging new API plant and core business growth post-merger withdrawal.

Prepared based on standalone unaudited results and disclosures as of August 1, 2025.

Note: This is an AI generated summary of the results. There may be inaccuracies in the summary. Please refer to the original document before making investment decisions.